NRC

NRC HEALTH (National Research Corporation) - 10-Q Summary

Business Context and Reporting Period

Company: National Research Corporation (NRC HEALTH)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: NRC provides survey-based performance measurement, analysis, tracking, improvement services, and governance education to the healthcare industry in the U.S. and Canada. The company's growth is driven by demand for performance measurement and public reporting programs.

Key Financial Metrics

Note: Total Debt includes current portion of note payable ($685,806) and long-term note payable ($6,077,260). Working capital is calculated as Current Assets minus Current Liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 12% for the quarter and 19.9% for the six-month period compared to the prior year. This growth is primarily attributed to the acquisition of The Governance Institute (TGI) in May 2006, which contributed an additional $3.4 million in revenue for the six-month period, alongside increased scope of work from existing clients.
• Profitability: Operating income margins improved to 22.5% for the six months ended June 30, 2007, compared to 20.1% in the prior year. This was driven by a higher mix of higher-margin products.
• Expense Trends: Direct expenses increased 19.1% year-over-year for the six-month period, largely due to servicing increased revenue and TGI-related costs (conference costs, salaries). Selling, general, and administrative (SG&A) expenses increased 10.0%, primarily due to salary increases related to TGI.
• Debt Reduction: Total debt decreased significantly from approximately $12.1 million in the prior year to $6.8 million. The company paid down the revolving credit facility, which had a zero balance as of June 30, 2007.
• Cash Flow: Net cash provided by operating activities surged to $7.5 million for the six months ended June 30, 2007, compared to $2.2 million in the prior year, driven by strong net income and changes in deferred revenue.

Guidance, Outlook, and Risks

• Liquidity: Management believes capital resources and operating cash flow are adequate to meet projected needs. The company expects to fund capital expenditures (budgeted at $1.5 million for 2007) through operations.
• Debt Maturity: The revolving credit facility matured on July 31, 2007. Management expects to extend the term for at least one year. The term note matures in May 2013.
• Capital Allocation: The company paid $1.6 million in cash dividends during the six-month period. A stock repurchase program remains active with approximately 692,534 shares remaining available for purchase.
• Risks: No material changes to risk factors were reported since the 2006 Annual Report. Key risks remain tied to the healthcare industry's demand for performance measurement services and compliance with debt covenants.
• Unusual Items: The company adopted FIN 48 (Accounting for Uncertainty in Income Taxes) effective January 1, 2007, with no material impact on unrecognized tax benefits. The company also recognized non-cash share-based compensation of $562,304 for the six-month period.

Investor Verification Checklist

• Debt Extension: Verify the status of the revolving credit facility extension, which matured July 31, 2007, shortly after the reporting period.
• Deferred Revenue: Review the $11.0 million in "Billings in excess of revenue earned" (deferred revenue) to understand the timing of future revenue recognition.
• Acquisition Integration: Assess the ongoing integration and performance contribution of The Governance Institute (TGI) to ensure sustained revenue growth.
• Working Capital: Monitor the working capital deficiency of $415,000, although it has improved from $1.5 million in the prior year-end.
• Share Repurchases: Track the execution of the remaining 692,534 shares authorized for repurchase under the current program.